REG - Futura Medical PLC - Board Appointment

Futura MedicalAnnouncement

31/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250331:nRSe8110Ca&default-theme=true

RNS Number : 8110C  Futura Medical PLC  31 March 2025

31 March 2025

 

Futura Medical plc

Board Appointment

Futura Medical plc (AIM: FUM), the consumer healthcare company behind
Eroxon(®), that specialises in the development and global commercialisation
of innovative and clinically proven sexual health products, is pleased to
announce the appointment of Harmesh Suniara to the Board as a Non-executive
Director, with immediate effect

 

Harmesh has over 17 years' experience of working in investment management,
with a particular focus on UK small and mid-cap equities. Since 2017 he has
worked as a Portfolio Manager at Lombard Odier Asset Management (Europe)
Limited, and from 2007, he was an Investment Manager at Henderson Volantis
Capital and Gartmore Investment Management.

 

Funds or accounts managed on a discretionary basis by Lombard Odier Asset
Management (Europe) Limited  hold in aggregate 86,781,198 ordinary shares of
Futura Medical, representing 28.56% of Futura Medical's issued share capital.

 

 

Jeff Needham, Chairman of Futura, commented:

"I am delighted to welcome Harmesh to the Board of Futura.  We look forward
to working with him as we continue our journey of meeting the unmet demand for
sexual health products and take advantages of the opportunities available to
us."

The following disclosures in relation to the appointment of Harmesh Kumar
Suniara, aged 54, are required pursuant to Schedule 2(g) of the AIM Rules for
Companies:

 

 Current                         Past 5 years
 C4X Discovery Holdings Limited
 IQE Plc
 Actual Experience Plc

Harmesh Suniara was a Director at Actual Experience Plc, which entered
administration on 14 November 2023.

 

No further information is required to be disclosed pursuant to AIM Rule 17 and
Schedule 2(g) of the AIM Rules for Companies.

 

Contacts:

 Futura Medical plc             James Barder                                            investor.relations@futuramedical.com

                                                       (mailto:Investor.relations@futuramedical.com)
                                Chief Executive Officer

                                                       +44 (0)1483 685 670
                                Angela Hildreth

                                                       www.futuramedical.com (http://www.futuramedical.com/)
                                Finance Director and COO

 Panmure Liberum                Emma Earl, Will Goode, Mark Rogers (Corporate Finance)  +44 (0)20 3100 2000

 Nominated Adviser              Rupert Dearden (Corporate Broking)

 and Broker

 Stifel                         Alan Selby                                              +44 (0)207 710 7600

 Joint Broker                   Ben Maddison

                                Ben Good

 Alma Strategic Communications  Rebecca Sanders-Hewett                                  +44 (0)20 3405 0205

                                Sam Modlin                                              futura@almastrategic.com

                                Will Ellis Hancock

 

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon(®) and products WSD4000 and
Eroxon(®) Intense. Our core strength lies in our research, development and
commercialisation of topically delivered gel formulations in sexual health
products.

Sexual health issues are prevalent in both men and women. ED impacts 1 in 5
men globally across all adult age brackets, with approximately half of all men
over 40 experiencing ED and 25% of all new diagnoses being in men under 40.
Around 60% of women experience at least one symptom of sexual dysfunction, and
only one in four women seek professional help, and remain chronically
underserved.

Eroxon(®), Futura's clinically proven lead product, has been developed for
the treatment of Erectile Dysfunction ("ED"). The highly differentiated
product, which is the only topical gel treatment for ED available over the
counter and helps men get an erection in ten minutes, addresses significant
unmet needs in the ED market. Eroxon(®) has been nominated for a number of
healthcare industry awards and has won two to-date.

Futura has distribution partners in place in a number of major consumer
markets including Haleon in the US, the largest market for ED in the world,
and Cooper Consumer Health in Europe.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABLGDXIXXDGUG